Anti-Siglec-15 antibodies and uses thereof
This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to Siglec-15 comprising: VH-CDR1, VH-CDR2, VH CDR3, VL-CDR1, VL-CDR2 and VL CDR3 sequences identical to the VH-CDR1, VH-CDR2, VH CDR3, VL-CDR1, VL-CDR2 and VL CDR3 sequences corresponding to SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively.
2. An isolated antibody or antigen-binding fragment thereof according to claim 1 , wherein said antibody or antigen-binding fragment thereof induces endocytosis of Siglec-15 at a rate where the half-life of endogenous surface Siglec-15 on human myelogenous leukemia K562 cells is less than about 5 minutes, less than about 4 minutes, or less than about 3 minutes.
3. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is at least 95% identical to SEQ ID NO:1 and at least 95% identical to SEQ ID NO:2.
4. The antibody or antigen-binding fragment thereof of claim 1 , which is humanized, chimeric, fully human, a Fab fragment, a Fab′ fragment, a F(ab)2 fragment, or a single chain Fv (scFv) fragment.
5. The isolated antibody or antigen-binding fragment thereof of claim 1 comprising SEQ ID NO: 1 and SEQ ID NO:2.
6. An isolated cell producing the antibody or antigen-binding fragment thereof of claim 1 .
7. A method of making the antibody or antigen-binding fragment thereof of claim 1 , comprising (a) culturing an isolated cell producing the antibody or fragment thereof; and (b) isolating said antibody or fragment thereof from said cultured cell.
8. An immunoconjugate having the formula (A)-(L)-(C) or (C)-(L)-(A), wherein:
(A) is an antibody or antigen binding fragment thereof of claim 1 ;
(L) is a linker; and
(C) is a cytotoxic agent; and
wherein said linker (L) links (A) to (C).
9. A composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a carrier.
10. The isolated antibody or antigen-binding fragment thereof of claim 1 comprising: (a) a VH sequence at least 90%, 95% or 100% identical to the amino acid sequence of SEQ ID NO:1; and (b) a VL sequence at least 90%, 95% or 100% identical to the amino acid sequence of SEQ ID NO:2.